AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
18 Aug 2016 01:00 PM
RNS
Director Declaration
16 Aug 2016 07:00 AM
RNS
AstraZeneca completes agreement with LEO Pharma
10 Aug 2016 02:41 PM
RNS
ASTRAZENECA ANNOUNCES INVESTMENT IN MODERNA
09 Aug 2016 07:00 AM
RNS
ASTRAZENECA UPDATE ON SELUMETINIB PHASE III TRIAL
01 Aug 2016 02:30 PM
RNS
Total Voting Rights
01 Aug 2016 11:00 AM
RNS
Director/PDMR Shareholding
28 Jul 2016 07:00 AM
RNS
AZN: H1 2016 Results
27 Jul 2016 09:00 AM
RNS
Notice of Results
19 Jul 2016 02:15 PM
RNS
QTERN (saxa/dapa) EU approved for type-2 diabetes
18 Jul 2016 07:00 AM
RNS
TAGRISSO MET PRIMARY ENDPOINT IN PHASE III TRIAL
14 Jul 2016 12:07 PM
RNS
Second Price Monitoring Extn
14 Jul 2016 12:02 PM
RNS
Price Monitoring Extension
13 Jul 2016 07:00 AM
RNS
AZ resolves Faslodex patent litigation in the US
01 Jul 2016 05:30 PM
RNS
Total Voting Rights
01 Jul 2016 07:00 AM
RNS
AZ enters licensing agreements with LEO Pharma
28 Jun 2016 07:00 AM
RNS
Zavicefta approved in EU
23 Jun 2016 07:00 AM
RNS
AstraZeneca updates on Flumist vaccine in the US
14 Jun 2016 03:00 PM
RNS
Director/PDMR Shareholding
09 Jun 2016 07:03 AM
RNS
AZ agreement with Aspen for anaesthetics portfolio
03 Jun 2016 07:00 AM
RNS
AZ completes US licensing agreement with Ironwood
02 Jun 2016 07:00 AM
RNS
AZ LICENSES ZURAMPIC TO GRÜNENTHAL GMBH
01 Jun 2016 12:00 PM
RNS
Block listing Interim Review
01 Jun 2016 11:30 AM
RNS
Total Voting Rights
27 May 2016 12:36 PM
RNS
POSITIVE CHMP OPINION IN EU FOR SAXA/DAPA
27 May 2016 07:03 AM
RNS
Positive results from AstraZeneca Faslodex trial
27 May 2016 07:00 AM
RNS
AstraZeneca receives CRL from US FDA for ZS-9
23 May 2016 04:00 PM
RNS
Director/PDMR Shareholding
18 May 2016 07:00 AM
RNS
TOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL
17 May 2016 07:00 AM
RNS
POSITIVE BENRALIZUMAB RESULTS IN SEVERE ASTHMA
12 May 2016 07:00 AM
RNS
SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN US
11 May 2016 05:30 PM
RNS
Publication of Final Terms
09 May 2016 05:35 PM
RNS
Launch and pricing of EUR2.2bn bond issues
05 May 2016 03:00 PM
RNS
Publication of a Prospectus
03 May 2016 01:30 PM
RNS
Total Voting Rights
03 May 2016 07:01 AM
RNS
AstraZeneca completes divestment of Imdur
03 May 2016 07:00 AM
RNS
AZ COMPLETES ACQUISITION OF TAKEDA RESPIRATORY
29 Apr 2016 05:30 PM
RNS
Result of AGM
29 Apr 2016 12:46 PM
RNS
POSITIVE CHMP OPINION FOR CAZ AVI
29 Apr 2016 07:00 AM
RNS
AZN: 1st Quarter Results
28 Apr 2016 09:00 AM
RNS
Notice of Results
26 Apr 2016 09:29 AM
RNS
AZ enters US licensing agreement with Ironwood
26 Apr 2016 07:01 AM
RNS
BEVESPI AEROSPHERE APPROVED BY US FDA FOR COPD
08 Apr 2016 07:00 AM
RNS
AZ TO CONTINUE PIVOTAL ALZHEIMER'S CLINICAL TRIAL
01 Apr 2016 11:30 AM
RNS
Total Voting Rights
29 Mar 2016 07:00 AM
RNS
TAGRISSO APPROVED IN JAPAN FOR CANCER PATIENTS
24 Mar 2016 03:00 PM
RNS
Director/PDMR Shareholding
23 Mar 2016 07:00 AM
RNS
AZ reports results from Brilinta stroke trial
18 Mar 2016 10:30 AM
RNS
Notice of AGM
08 Mar 2016 06:29 PM
RNS
Filing of Form 20-F with SEC
08 Mar 2016 12:00 PM
RNS
Annual Financial Report
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100